摘要糖尿病前期的诊断标准迄今尚不统一，干预糖尿病前期能否带来微血管和大血管的长期获益也尚存争议。然而，在正常血糖与糖尿病之间的中间高血糖状态所产生的危害是明确的。糖尿病前期包括空腹血糖受损(IFG)、糖耐量受损(IGT)和IFG＋IGT三类人群。目前对于IGT人群早期干预获益的证据比较充分，但缺乏单纯IFG人群早期干预对糖尿病及其并发症具有预防作用的证据。干预的方法应当首选以调整饮食和增加运动为主的生活方式干预，对于那些生活方式干预难以依从，但有预防意愿、经济条件允许、且经医生判断能够从药物干预中获益的人群，可以考虑药物干预。识别糖尿病前期的目的是，希望通过生活方式干预和(或)药物干预，预防或延缓该人群发展成为糖尿病，甚或预防糖尿病慢性并发症的发生。制订本共识的目的是进一步强化预防糖尿病的观念，明确哪些人群应该重点干预，如何具体实施干预，从而为广大医生，特别是全科和基层医生，提供一个可供参考的工具。

abstractsThe criteria for the definition of prediabetes are not unified and whether prediabetes intervention has long-term microvascular and macrovascular benefits is also controversial. However, the harmfulness of intermediate hyperglycemic state between normoglycemia and diabetes is clear. Prediabetes includes impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and a combined form of IFG+ IGT. So far, evidence that early intervention is beneficial for diabetes prevention has been sufficient in the subgroup of IGT but not in that of isolated IFG. Lifestyle intervention, including diet control and physical exercise, is a cornerstone for the management of prediabetes. Pharmacological intervention is only considered for individuals who are difficult to adhere to lifestyle intervention, though having a willing to prevent the disease, or who are allowed by economic condition and are able to benefit from the intervention as judged by doctors. The purpose of identifying prediabetes is to initiate lifestyle intervention and(or) pharmacological intervention to prevent or delay the progression of prediabetes to diabetes or even to delay or avoid chronic diabetic complications. This consensus is aimed to strengthen the concept of diabetes prevention, to identify the key subgroups of prediabetes that should receive the intervention and to know how the intervention is implemented, thereby providing a practical tool for doctors, especially for general practitioners and primary care doctors.